Puma Biotechnology, Inc.PBYINASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank64
3Y CAGR+27.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+27.9%/yr
Quarterly compound
Percentile
P64
Within normal range
vs 3Y Ago
2.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.41% |
| Q3 2025 | -8.65% |
| Q2 2025 | 5.85% |
| Q1 2025 | 2.18% |
| Q4 2024 | 0.91% |
| Q3 2024 | -32.46% |
| Q2 2024 | 14.81% |
| Q1 2024 | 7.76% |
| Q4 2023 | -8.98% |
| Q3 2023 | -7.40% |
| Q2 2023 | 6.50% |
| Q1 2023 | -10.20% |
| Q4 2022 | 4.50% |
| Q3 2022 | 16.45% |
| Q2 2022 | 0.85% |
| Q1 2022 | -9.17% |
| Q4 2021 | -13.89% |
| Q3 2021 | -33.81% |
| Q2 2021 | 39.56% |
| Q1 2021 | -1.29% |
| Q4 2020 | -3.35% |
| Q3 2020 | 0.86% |
| Q2 2020 | -5.14% |
| Q1 2020 | 2.87% |
| Q4 2019 | -4.22% |
| Q3 2019 | -6.34% |
| Q2 2019 | -26.31% |
| Q1 2019 | 10.98% |
| Q4 2018 | 43.86% |
| Q3 2018 | -28.99% |
| Q2 2018 | 9.65% |
| Q1 2018 | 18.45% |
| Q4 2017 | -4.89% |
| Q3 2017 | 30.33% |
| Q2 2017 | 35.48% |
| Q1 2017 | 11.52% |
| Q4 2016 | 17.67% |
| Q3 2016 | 14.33% |
| Q2 2016 | 11.11% |
| Q1 2016 | 14.99% |